Stockreport

Century Therapeutics: Cell Therapy Biotech With Expanded Potential Of CNTY-101 [Seeking Alpha]

Century Therapeutics, Inc.  (IPSC) 
PDF of patients with relapsed/refractory CD19-positive non-Hodgkin lymphoma patients. The global non-Hodgkin Lymphoma market is expected to surge to $11 billion by 2029. [Read more]